Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...

Changes in walking, balance and mobility are common and bothersome symptoms of Parkinson’s. They may look different from person to person — and even within the same person, depending on time and ...

Every person diagnosed with Parkinson’s disease (PD) embarks on a unique journey. There is no standard path, and, for many, this proves to be among the most challenging aspects of the disease.

A little more than 20 years ago, scientists thought Parkinson’s disease (PD) had no genetic connection. Today, scientists have linked about 10 percent of Parkinson’s cases to a direct genetic cause.

Many people prefer not to talk about their Parkinson’s disease (PD), but those who are able to discuss it openly seem to find it less burdensome. A Parkinson’s diagnosis rarely affects just one person ...

Search for topics, articles, videos, research, etc... For me, All Grit. No Quit. is like those last two-tenths of a mile in a marathon. You want to quit, but thousands are cheering for you, so you ...

This program is part of a research study. Genetic screening is currently open to people with Parkinson’s disease (PD) who have a family history of PD or Ashkenazi Jewish ancestry. Additional groups ...

Alice Nieuwboer, PhD, heads the Neurorehabilitation Research Group at KU Leuven. She has made original contributions to gait and motor learning research in Parkinson’s disease. Her work highlighted ...

Guy Boeckxstaens obtained his medical degree in 1987 and his PhD degree in 1991. In 1994, he completed his clinical training in internal medicine and gastroenterology and accepted a staff position in ...

Path to Prevention (P2P) is a Phase 2A platform trial that leverages Parkinson’s Precision Medicine Initiative (PPMI) infrastructure to evaluate investigational products in participants with neuronal ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...

Lewy body dementia (LBD) is a common, under-recognized and often misdiagnosed brain disease that affects more than 1 million people in the United States. Lewy body dementia is a progressive brain ...